Oslo - Delayed Quote NOK

Navamedic ASA (NAVA.OL)

33.50

-0.30

(-0.89%)

At close: April 18 at 4:25 PM GMT+2

Navamedic welcomes new shareholders

Navamedic (OSE: NAVA) is pleased to welcome new shareholders and delighted to see existing shareholders acquire a bigger stake following Ingerø Reiten Investment Company's (IRIC) sale of its entire 17.1 percent interest in the company.

PR Newswire last month

NAVA.OL
-0.89%
Navamedic ASA: Notification of major shareholding and mandatory notification of trade

Ingerø Reiten Investment Company AS ("IRIC") has today sold all of its shares in the Nordic pharmaceutical company Navamedic ASA. The shares were sold for 32 kroner per share, for total gross proceeds of approximately NOK 95 million, or about 2.7 times the amount invested. IRIC has been Navamedic's principal owner and strategic partner since 2019. IRIC will use part of the proceeds to strengthen its balance sheet by paying off debt.

PR Newswire last month

NAVA.OL
-0.89%
Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives

Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announced its results for the fourth quarter and for the full year 2023. Revenues for the year was up 34 per cent to NOK 512 million, mainly by organic growth. For the first time all three product categories were above the NOK 100 million mark.

PR Newswire 2 months ago

NAVA.OL
-0.89%
Navamedic ASA: Invitation to 2023 4th quarter presentation

Navamedic ASA (OSE: Nava) will be presenting its fourth quarter 2023 results on Thursday, February 15, 2024. The presentation will be held at Dronning Eufemias gate 16 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial-results/

PR Newswire 2 months ago

NAVAO.ST
Navamedic ASA: Renewed contract signed with Vitaflo International Limited

Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces it has renewed its contract with Vitaflo International Limited (Vitaflo International), granting Navamedic the exclusive rights to market and distribute Vitaflo International's medical nutrition products across the Nordic region for an additional five years.

PR Newswire 3 months ago

NAVA.OL
-0.89%
Navamedic and Orion Corporation sign non-binding term sheet for Flexilev®in Europe

Navamedic ASA and Orion Corporation ("Orion") have today signed a non-binding term sheet for a licensing- and supply agreement for Flexilev®, including the Orafid dispenser, across Europe, not including Sweden, Norway, Denmark, and Iceland, where Navamedic will market and sell the product. Flexilev® is a novel prescription treatment for Parkinson's disease and was added to Navamedic's product portfolio following the acquisition of Sensidose AB in May 2023.

PR Newswire 4 months ago

NAVA.OL
-0.89%
Navamedic ASA: Record high quarter with above 50 percent growth

Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces its results for the third quarter of 2023. With growth across the company's three core product areas, Prescription Drugs (RX), Consumer Health and Hospital, year to date, Navamedic has delivered another record quarter. Revenues for the third quarter amounted to NOK 141 million, corresponding to a 51.9 per cent increase Year-over-Year.

PR Newswire 5 months ago

NAVA.OL
-0.89%
Navamedic ASA: Invitation to 2023 3rd quarter presentation

Navamedic ASA (OSE: NAVA) will be presenting its third quarter 2023 results on Wednesday, November 1, 2023. The presentation will be held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial-results/

PR Newswire 5 months ago

NAVA.OL
-0.89%
Navamedic ASA - Registration of share capital increase

Reference is made to the stock exchange announcement published on 18 August 2023 by Navamedic ASA (the "Company") regarding the board of directors' resolution to increase the Company's share capital in connection with the exercise of employee share options. The share capital increase pertaining to the exercised share options has now been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The new share capital of the Company is NOK 12,841,054.98 divided into

PR Newswire 7 months ago

NAVA.OL
-0.89%
Navamedic ASA - Mandatory notification of trade by primary insider

Reference is made to the stock exchange announcement published earlier today, on 18 August 2023 by Navamedic ASA (the "Company" or "Navamedic"), regarding the board of directors' resolution to increase the Company's share capital with NOK 92,500 by the issuance of 125,000 new shares, in order to facilitate the settlement of exercise of 125,000 share options in the Company.

PR Newswire 7 months ago

NAVA.OL
-0.89%
NAVAMEDIC ASA: Resolution to increase the share capital in connection with exercise of employee options

The board of directors of Navamedic ASA (the "Company"), has today, on 18 August 2023, in accordance with the authorisation granted to it by the general meeting on 1 June 2023, resolved to increase the Company's share capital by NOK 92,500 by issuance of 125,000 new shares, each with a nominal value of NOK 0.74, in order to facilitate the settlement of exercise of 125,000 share options. The exercise prices are NOK 14.46 per share for 25,000 of the new shares and NOK 19.00 per share for 100,000 o

PR Newswire 7 months ago

NAVA.OL
-0.89%
Navamedic ASA: Significant growth across the business

Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces its results for the second quarter and first half of 2023. Having experienced strong growth across the business, Navamedic grew its revenues for the first half of 2023 by 41.7 per cent, amounting to NOK 245.7 million.

PR Newswire 8 months ago

NAVA.OL
-0.89%
Navamedic ASA: Invitation to 2023 2nd quarter presentation

Navamedic ASA (OSE: Nava) will be presenting its second quarter 2023 results and publish its first half 2023 report on Friday, August 11, 2023. The presentation will be held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial-results/.

PR Newswire 8 months ago

NAVA.OL
-0.89%
Navamedic ASA: Minutes of Annual General Meeting

The Annual General Meeting of Navamedic ASA was held today at 10:00 CEST. All items on the agenda were resolved in accordance with the board of directors' proposals and the nomination committee's recommendations. A copy of the minutes from the Annual General Meeting is attached to this notice and will also be made available on the Company's webpage www.navamedic.com.

PR Newswire 10 months ago

NAVA.OL
-0.89%
Updated recommendation by the nomination committee of Navamedic ASA

Following Navamedic ASA's acquisition of Sensidose AB, the nomination committee recommends that Åsa Kornfeld, previous Board member in Sensidose AB, is elected as a new Navamedic ASA Board member in addition to Terje Bakken (Chairman), Narve Reiten, Jostein Davidsen, Annika Kollén and Edmée Steenken on the Annual General Meeting on June 1st, 2023.

PR Newswire 10 months ago

NAVA.OL
-0.89%
Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer

Following the closing of the acceptance period in the previously announced public offer, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, will become the owner of 96.33 per cent of the share capital and votes and 93.16 per cent of the series TO 1 warrants ("Warrants") in Sensidose Aktiebolag ("Sensidose).

PR Newswire 10 months ago

NAVA.OL
-0.89%
Navamedic ASA Q1 2023: Another strong quarter

Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces its results for the first quarter of 2023. Navamedic experienced good momentum across the business and delivered another strong quarter, with record high revenues of NOK 121.7 million, representing an increase of 93.3 per cent compared to the first quarter of 2022.

PR Newswire 11 months ago

NAVA.OL
-0.89%
Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag

Navamedic ASA (OSE: NAVA), a Nordic pharma company and provider of high-quality products to hospitals and pharmacies, has today amended its cash offer to acquire the shares and warrants in Sensidose AB not already owned by Navamedic ASA (the "Offer"). The Sensidose shares and warrants of series TO 1 are currently listed on Spotlight Stock Market in Sweden.

PR Newswire 11 months ago

NAVA.OL
-0.89%
Navamedic ASA: Annual Report for 2022

Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, announce that the company has published its Annual Report for 2022, which was approved by the Board of Directors on 27 April 2023.

PR Newswire 11 months ago

NAVA.OL
-0.89%
Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB

Navamedic ASA (OSE: NAVA), a Nordic pharma company and provider of high-quality products to hospitals and pharmacies, has today amended its cash offer to acquire all shares in Sensidose AB (the "Offer") and at the same time agreed to purchase 6,837,016 shares in Sensidose AB representing 57.2% of the outstanding shares. The Sensidose shares are currently listed on Spotlight Stock Market in Sweden.

PR Newswire 11 months ago

NAVA.OL
-0.89%

Performance Overview

Return	NAVA.OL	OBX Total Return Index
YTD	-8.72%	+5.24%
1-Year	-16.25%	+12.21%
3-Year	+29.84%	+30.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Navamedic ASA (NAVA.OL)

Navamedic welcomes new shareholders

Navamedic ASA: Notification of major shareholding and mandatory notification of trade

Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives

Navamedic ASA: Invitation to 2023 4th quarter presentation

Navamedic ASA: Renewed contract signed with Vitaflo International Limited

Navamedic and Orion Corporation sign non-binding term sheet for Flexilev®in Europe

Navamedic ASA: Record high quarter with above 50 percent growth

Navamedic ASA: Invitation to 2023 3rd quarter presentation

Navamedic ASA - Registration of share capital increase

Navamedic ASA - Mandatory notification of trade by primary insider

NAVAMEDIC ASA: Resolution to increase the share capital in connection with exercise of employee options

Navamedic ASA: Significant growth across the business

Navamedic ASA: Invitation to 2023 2nd quarter presentation

Navamedic ASA: Minutes of Annual General Meeting

Updated recommendation by the nomination committee of Navamedic ASA

Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer

Navamedic ASA Q1 2023: Another strong quarter

Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag

Navamedic ASA: Annual Report for 2022

Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB

Performance Overview